NORTHWESTERN UNIVERSITY
Total received in grants · trailing 12 months
$2.7M
$0for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $162.9B in tracked grants
2separate grants, trailing 12 months
NORTHWESTERN UNIVERSITY has received $2.7M across 2 federal grants of $1M or more on record.
Data as of July 24, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Health and Human Services | COMBINATION ANTIBIOTIC THERAPY FOR PSEUDOMONAS VAP (COMBAT PSEUDO VAP): A PRAGMATIC TRIAL - PROJECT SUMMARY/ABSTRACT THE PRIMARY OBJECTIVE OF THIS PROPOSAL IS TO PERFORM A PHASE 2, PRAGMATIC, STRATIFIED, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER CLINICAL TRIAL OF TOBRAMYCIN/Β-LACTAM COMBINATION ANTIBIOTIC THERAPY (COMBAT) COMPARED TO Β-LACTAM MONOTHERAPY FOR TREATMENT OF PSEUDOMONAS AERUGINOSA (PSA) VENTILATED HOSPITAL-ACQUIRED/VENTILATOR-ASSOCIATED PNEUMONIA (VHAP/VAP). PSA-VHAP/VAP, PARTICULARLY WHEN DUE TO MULTIDRUG-RESISTANT ISOLATES, IS ASSOCIATED WITH INCREASED MORTALITY AND LENGTH OF STAY, HIGH CLINICAL FAILURE RATES, AND HIGH RECURRENCE RATES COMPARED TO OTHER PATHOGENS, ESPECIALLY WHEN TREATED WITH A SINGLE Β-LACTAM ANTIBIOTIC. WITH A PAUCITY OF HIGH-QUALITY DATA, CURRENT PROFESSIONAL SOCIETY GUIDELINES FOR TREATMENT OF VHAP/VAP EQUIVOCATE ON THE NEED FOR COMBAT; RECOMMENDING AGAINST IT FOR DEFINITIVE THERAPY IN MOST CASES OF PSA-HABP BUT OFFERING A “WEAK RECOMMENDATION” IN FAVOR OF DEFINITIVE COMBAT FOR SEVERELY ILL PATIENTS OR THOSE WITH SECONDARY BACTEREMIA. HOWEVER, CONCERNS ABOUT ACUTE KIDNEY INJURY (AKI), THE MOST SIGNIFICANT ADVERSE SIDE EFFECT OF AMINOGLYCOSIDES, LIMIT CLINICAL AMINOGLYCOSIDE USE, EVEN IN SITUATIONS WHERE USE IS RECOMMENDED BY GUIDELINES. BECAUSE OF THIS MAJOR CONCERN, THE PRIMARY ENDPOINT OF THIS PHASE 2 TRIAL WILL BE TO DEMONSTRATE EQUIVALENCE OF RATES OF AKI IN PATIENTS RANDOMIZED TO COMBAT TREATED WITH 5-DAYS OF DOSE-OPTIMIZED TOBRAMYCIN. WE WILL USE THE RISK, INJURY, FAILURE, LOSS OF KIDNEY FUNCTION, AND END-STAGE KIDNEY DISEASE (RIFLE) CRITERIA, WHICH ARE SENSITIVE CRITERIA FOR AKI DIAGNOSIS BASED ON LABORATORY TESTS (CREATININE) AND URINE VOLUME. FOR DIAGNOSIS AND MANAGEMENT OF VHAP/VAP, THE FOUR PARTICIPATING CENTERS ROUTINELY USE BRONCHOALVEOLAR LAVAGE (BAL) WITH QUANTITATIVE CULTURES SUPPLEMENTED WITH MULTIPLEX BACTERIAL PCR PANELS. THIS CUTTING-EDGE APPROACH OF BAL COMBINED WITH RAPID DIAGNOSTIC TESTING WILL ENABLE PROMPT, ACCURATE IDENTIFICATION OF PSA-VHAP/VAP, FACILITATING ENROLLMENT OF SUBJECTS EARLY IN THEIR PNEUMONIA COURSE WHEN THE IMPACT OF THERAPEUTIC INTERVENTIONS IS LIKELY TO BE GREATEST. OPEN-LABEL DOSE-OPTIMIZED STANDARD-OF-CARE ANTI-PSEUDOMONAL Β-LACTAMS WILL BE UTILIZED FOR BOTH ARMS, WITH CHOICE OF Β- LACTAM INDIVIDUALIZED BASED ON MULTIPLEX PCR RESISTANCE MARKERS, PRIOR ANTIBIOTIC AND PATHOGEN HISTORY, AND INDIVIDUAL CENTER STANDARDS. THE PRAGMATIC FLEXIBILITY IN Β-LACTAM CHOICE INCREASES THE GENERALIZABILITY OF RESULTS. AS A SECONDARY ANALYSIS (AIM2), WE WILL DETERMINE WHETHER TOBRAMYCIN/Β-LACTAM COMBAT FOR PSA-VHAP/VAP IS ASSOCIATED WITH IMPROVED CLINICAL EFFICACY, AS ASSESSED BY WIN RATIO ANALYSIS, COMPARED TO Β-LACTAM MONOTHERAPY. THE WIN RATIO METHODOLOGY IS A NOVEL ANALYTIC APPROACH THAT INCORPORATES MULTIPLE HIERARCHICAL ENDPOINTS WHILE ACCOUNTING FOR THE CLINICAL AND PATIENT-ORIENTED PRIORITY OF EACH COMPONENT ENDPOINT. WHILE WE ARE COMMITTED TO UTILIZING THE WIN RATIO, THE OPTIMAL ENDPOINT COMPOSITION FOR INCLUSION IN A PNEUMONIA WIN RATIO ALGORITHM IS UNCLEAR. AS THE FIRST VHAP/VAP RCT TO USE THE WIN RATIO ANALYSIS, THIS TRIAL IS IDEAL TO OPTIMIZE ENDPOINT ALTERNATIVES. THUS, IN AIM3 WE WILL INVESTIGATE VARIATIONS TO THE HIERARCHICAL ENDPOINT COMPOSITION THAT BEST REFLECT CLINICAL AND PATIENT PRIORITIES AND PROVIDE PARSIMONIOUS DIFFERENTIATION OF TREATMENT EFFICACY. | $1,478,563 |
| Department of Health and Human Services | NEURONAL AND NETWORK MECHANISMS OF ELECTROCORTICAL STIMULATION - ELECTROCORTICAL STIMULATION (ECS) HAS BEEN USED FOR FUNCTIONAL MAPPING FOR MANY DECADES TO IDENTIFY BRAIN AREAS THAT ARE “CRITICAL” FOR SPEECH AND LANGUAGE (I.E., THAT IMPAIR FUNCTION WHEN STIMULATED) PRIOR TO EPILEPSY OR TUMOR SURGERY. IT ALSO IS USED TO MODULATE NEURAL ACTIVITY, E.G., IN DIRECTLY TREATING EPILEPSY OR PAIN. HOWEVER, DESPITE ITS LONG HISTORY OF CLINICAL USE, THE PRECISE MECHANISMS OF ECS ARE POORLY UNDERSTOOD, BOTH ON NEURONAL AND NETWORK SCALES. FOR EXAMPLE, IT IS NOT KNOWN HOW DIFFERENT CORTICAL LAYERS AND CELL TYPES RESPOND TO ECS, NOR WHETHER ECS’ EFFECTS ON BEHAVIOR ARE DUE TO AFFECTING ONLY THE LOCAL CORTEX VS. UNDERLYING WHITE MATTER. THE LONG-TERM GOAL OF THIS RESEARCH IS TO UNDERSTAND HOW ECS INTERACTS WITH THE BRAIN. THE OBJECTIVES OF THIS PROPOSAL ARE TO DETERMINE THE LOCAL EFFECTS OF ECS ON CORTICAL NEURONS, AND TO DETERMINE THE EFFECTS OF ECS ON THE CORTICAL NETWORK AND SUBCORTICAL WHITE MATTER. WE WILL TEST THE PREDICTIONS OF MULTIPLE COMPUTATIONAL MODELLING AND INDIRECT EXPERIMENTAL STUDIES. ONE OF THESE THAT ECS PREFERENTIALLY ACTIVATES CELLS IN SUPERFICIAL CORTICAL LAYERS WITH BROAD PROJECTIONS, COULD HELP EXPLAIN HOW FOCAL STIMULATION CAUSES WIDESPREAD EFFECTS. WE HYPOTHESIZE THAT THE ANATOMIC AND FUNCTIONAL CONNECTIVITY PATTERNS OF A CORTICAL SITE DETERMINE ITS SIGNIFICANCE TO THE LANGUAGE NETWORK. THAT IS, NODES THAT FORM CONNECTIONS AMONG MULTIPLE REGIONS ARE MORE LIKELY TO BE CRITICAL. WE ALSO HYPOTHESIZE THAT ECS CAUSES BEHAVIORAL CHANGES BY AFFECTING BOTH THE CORTEX AND UNDERLYING WHITE MATTER. THE SPECIFIC AIMS OF THE PROJECT ARE 1) TO DETERMINE THE EFFECTS OF ECS ON A NEURONAL SCALE, 2) TO DETERMINE THE RELATIONSHIP BETWEEN ECS’ EFFECTS AND CORTICAL CONNECTIVITY PATTERNS, AND 3) TO INVESTIGATE THE EXTENT TO WHICH ECS’ EFFECTS ARE DUE TO ACTIVATING UNDERLYING WHITE MATTER. THIS PROJECT IS INNOVATIVE IN ITS USE OF NANOMESH, ΜECOG (ELECTROCORTICOGRAPHY) ARRAYS TO ENABLE SIMULTANEOUS ECS AND TWO-PHOTON CALCIUM IMAGING OF NEURONAL RESPONSES, AS WELL AS ITS NOVEL DYNAMIC NETWORK METRICS TO ANALYZE HUMAN CORTICAL CONNECTIVITY ON A MILLISECOND LEVEL. WE HAVE SHOWN THAT FOCAL CORTICAL COOLING ONLY AFFECTS THE CORTEX, AND NOT THE WHITE MATTER, AND WILL USE COOLING TO PROBE THE RELATIVE ROLES OF CORTEX AND WHITE MATTER IN ECS’ BEHAVIORAL EFFECTS. ACHIEVING OUR OBJECTIVES WILL BE SIGNIFICANT BECAUSE IT WILL IMPROVE FUNCTIONAL BRAIN MAPPING AND NEUROMODULATION. WE EXPECT THIS TO LEAD TO BETTER NEUROSURGICAL OUTCOMES FOR A VARIETY OF NEUROLOGIC DISORDERS, INCLUDING EPILEPSY, BRAIN TUMORS, AND CHRONIC PAIN. WE ALSO EXPECT THIS PROPOSAL WILL ENABLE OTHER STUDIES USING STIMULATION TO INVESTIGATE CAUSALITY TO BE MORE PRECISE IN DEFINING AND UNDERSTANDING THEIR OUTCOMES. FINALLY, WE ANTICIPATE THIS PROPOSAL WILL ADVANCE OUR UNDERSTANDING OF HOW THE BRAIN ENCODES LANGUAGE. | $1,223,270 |